Boston Scientific Launches Neuromodulation Learning Institute To Enhance Clinical Education For Spinal Cord Stimulation Boston Scientific Corporation (NYSE: BSX) has launched its Neuromodulation Learning Institute™ (NLI), a clinical education program and online...

NATICK, Mass. , Aug. 10, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) has launched its Neuromodulation Learning Institute™ (NLI), a clinical education program and online resource center for healthcare providers to enhance their knowledge and awareness of spinal cord stimulation (SCS) technology, procedures and techniques. The Company made the announcement during the annual meeting of the International Spine Intervention Society (ISIS) occurring this week in Chicago .

(Photo: http://photos.prnewswire.com/prnh/20110810/NE50021 )

To complement these learning tools, Boston Scientific is also introducing its NLI iPhone®/iPad® app, an industry-first educational resource for healthcare providers using SCS to manage patients with chronic pain. It features surgical technique videos and access to a comprehensive SCS textbook, Spinal Cord Stimulation: Percutaneous Implantation Techniques , written by Paul Kries , M.D., and Scott Fishman , M.D.

"The NLI offers in-depth instruction on techniques critical to successful patient outcomes with SCS," said Thomas Simopoulos , M.D., Director of the Interventional Pain Service at the Arnold Pain Management Center, Beth Israel Deaconess Medical Center in Boston and Assistant Professor of Anesthesia at Harvard Medical School . "The new iPhone/iPad app is an excellent tool for training current and prospective pain physicians on spinal cord stimulation."

"This unique training forum will benefit physicians and their patients who suffer from chronic pain by offering healthcare providers a comprehensive, single source of SCS information," said Michael Onuscheck , Senior Vice President and President of Boston Scientific's Neuromodulation Division. "The Neuromodulation Learning Institute is dedicated to providing a continuum of physician training that will broaden understanding of SCS and advance the quality of patient care."

For additional information and to review the NLI's clinical training and educational offerings, visit www.NeuromodLearning.com . Healthcare providers may download the NLI iPhone/iPad app for free at www.NeuromodLearning.com/app and activate it by obtaining a unique passcode from their local Boston Scientific Neuromodulation representative.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com .

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding physician education, on-line training, new product launches, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

SOURCE Boston Scientific Corporation